These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34036680)

  • 1. Prevalence of multimorbidity and its impact on survival in people with motor neuron disease.
    Glasmacher SA; Kearns PKA; Larraz J; Stirland L; Mehta AR; Newton J; Weir CJ; Chandran S; Pal S;
    Eur J Neurol; 2021 Aug; 28(8):2756-2765. PubMed ID: 34036680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Prevalence and Management of Saliva Problems in Motor Neuron Disease: A 4-Year Analysis of the Scottish Motor Neuron Disease Register.
    Pearson I; Glasmacher SA; Newton J; Beswick E; Mehta AR; Davenport R; Chandran S; Pal S;
    Neurodegener Dis; 2020; 20(4):147-152. PubMed ID: 33902047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating Amyotrophic Lateral Sclerosis and Motor Neuron Disease Prevalence in Portugal Using a Pharmaco-Epidemiological Approach and a Bayesian Multiparameter Evidence Synthesis Model.
    Conde B; Winck JC; Azevedo LF
    Neuroepidemiology; 2019; 53(1-2):73-83. PubMed ID: 31117082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of amyotrophic lateral sclerosis and other motor neuron disease among men with benign prostatic hyperplasia: a population-based cohort study.
    Sørensen TT; Horváth-Puhó E; Nørgaard M; Ehrenstein V; Henderson VW
    BMJ Open; 2019 Jul; 9(7):e030015. PubMed ID: 31278107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiological characteristics of motor neuron disease in Chinese patients.
    Cui F; Liu M; Chen Y; Huang X; Cui L; Fan D; Pu C; Lu J; Zhou D; Zhang C; Yan C; Li C; Ding X; Liu Y; Li X; Jiang Y; Zhang J; Shang H; Yao X; Ding Y; Niu Q; Wang L
    Acta Neurol Scand; 2014 Aug; 130(2):111-7. PubMed ID: 24689740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology and survival trends of motor neurone disease in Northern Ireland from 2015 to 2019.
    McCluskey G; Duddy W; Haffey S; Morrison K; Donaghy C; Duguez S
    Eur J Neurol; 2022 Mar; 29(3):707-714. PubMed ID: 34748676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and prognostic features of ALS/MND in different phenotypes-data from a hospital-based registry.
    Wei QQ; Chen Y; Chen X; Cao B; Ou R; Zhang L; Hou Y; Shang H
    Brain Res Bull; 2018 Sep; 142():403-408. PubMed ID: 30232045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Onset, natural history and outcome in idiopathic adult motor neuron disease.
    Norris F; Shepherd R; Denys E; U K; Mukai E; Elias L; Holden D; Norris H
    J Neurol Sci; 1993 Aug; 118(1):48-55. PubMed ID: 8229050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Motor neuron disease mortality rates in New Zealand 1992-2013.
    Cao MC; Chancellor A; Charleston A; Dragunow M; Scotter EL
    Amyotroph Lateral Scler Frontotemporal Degener; 2018 May; 19(3-4):285-293. PubMed ID: 29382218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease.
    Ng L; Khan F; Young CA; Galea M
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD011776. PubMed ID: 28072907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The incidence and prevalence of motor neurone disease in South Australia.
    Luker J; Woodman R; Schultz D
    Amyotroph Lateral Scler Frontotemporal Degener; 2023 May; 24(3-4):195-202. PubMed ID: 35934980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Descriptive epidemiology of motor neuron disease in Benghazi, Libya.
    Radhakrishnan K; Ashok PP; Sridharan R; Mousa ME
    Neuroepidemiology; 1986; 5(1):47-54. PubMed ID: 3489194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The epidemiology of motor neurone disease in two counties in the southwest of England.
    Imam I; Ball S; Wright D; Hanemann CO; Zajicek J
    J Neurol; 2010 Jun; 257(6):977-81. PubMed ID: 20094727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurement of spinal cord atrophy using phase sensitive inversion recovery (PSIR) imaging in motor neuron disease.
    Olney NT; Bischof A; Rosen H; Caverzasi E; Stern WA; Lomen-Hoerth C; Miller BL; Henry RG; Papinutto N
    PLoS One; 2018; 13(11):e0208255. PubMed ID: 30496320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology of amyotrophic lateral sclerosis.
    Kurtzke JF
    Adv Neurol; 1982; 36():281-302. PubMed ID: 6983824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective observational cohort study of factors influencing trial participation in people with motor neuron disease (FIT-participation-MND): a protocol.
    Beswick E; Glasmacher SA; Dakin R; Newton J; Carson A; Abrahams S; Chandran S; Pal S
    BMJ Open; 2021 Mar; 11(3):e044996. PubMed ID: 33757953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Scottish Motor Neuron Disease Register: a prospective study of adult onset motor neuron disease in Scotland. Methodology, demography and clinical features of incident cases in 1989.
    J Neurol Neurosurg Psychiatry; 1992 Jul; 55(7):536-41. PubMed ID: 1640227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency of motor neuron diseases in a Mexico City referral center.
    Otero-Siliceo E; Arriada-Mendicoa N; Corona-Vázquez T
    Rev Invest Clin; 1997; 49(6):445-8. PubMed ID: 9528303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Global Burden of Motor Neuron Disease: An Analysis of the 2019 Global Burden of Disease Study.
    Park J; Kim JE; Song TJ
    Front Neurol; 2022; 13():864339. PubMed ID: 35528743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.